Information Provided By:
Fly News Breaks for February 13, 2020
Feb 13, 2020 | 12:51 EDT
Stifel analyst Paul Matteis lowered his price target for Alkermes to $20 from $23 and reiterates a Hold rating on the shares following the company's Q4 results. Alkermes looks well positioned to advance a pipeline that is early but expanding, Matteis tells investors in a post-earnings research note. While the analyst remains concerned about visibility into the growth potential for Vivitrol, he believes Alkermes' 2020 goals for Aristada "appear well within reach." This sets the company up fairly well into a late 2020 or early 2021 launch for ALKS 3831, contends Matteis. Nonetheless, the analyst remains cautious on near-term share upside from current levels. Alkermes is still early on the path toward leveraging its $1B-plus in sales into a "clear growth-oriented future," says Matteis.
News For ALKS From the Last 2 Days
Mar 1, 2021 | 09:53 EST
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Atotech (ATC) initiated with a Buy at Deutsche Bank, Jefferies and BofA, initiated with an Overweight at JPMorgan, initiated with an Outperform at Credit Suisse, RBC Capital and BMO Capital. 2. Sensei Biotherapeutics (SNSE) initiated with an Overweight at Piper Sandler, a Buy at Citi and an Outperform at Oppenheimer. 3. Boston Beer (SAM) initiated with an Overweight at Morgan Stanley. 4. Alkermes (ALKS) assumed with a Hold at Jefferies. 5. EyePoint (EYPT) initiated with an Outperform at Cowen. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.